ANGELO BEZERRA DE SOUZA FEDE
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
conferenceObject Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients not candidates for optimal primary surgery: Safety and effectivenes(2013) MIRANDA, Vanessa Costa; FEDE, Angelo Bezerra de Sousa; ANJOS, Carlos Henrique Dos; SILVA, Juliana Ribeiro da; SANCHEZ, Fernando Barbosa; BESSA, Lyvia Rodrigues da Silva; CARVALHO, Jesus Paula; ABDO FILHO, Elias; FREITAS, Daniela; BARROS, Laryssa Almeida Borges de; SILVA, Samantha Cabral Severino da; ESTEVEZ-DIZ, Maria Del Pilar- Return to work after breast cancer diagnosis: An observational prospective study in Brazil(2018) LANDEIRO, Luciana C. G.; GAGLIATO, Debora M.; FEDE, Angelo B.; FRAILE, Natalia M.; LOPEZ, Rossana M.; FONSECA, Leonardo G. da; PETRY, Vanessa; TESTA, Laura; HOFF, Paulo M.; MANO, Max S.Background In North America and Europe, return-to-work (RTW) rates vary among breast cancer (BC) survivors, from 24% to 66% and from 53% to 82% at 6 and 36 months after diagnosis, respectively. To date, there is a lack of data on RTW rates after BC diagnosis in Latin America. Therefore, the primary objectives of this study were to define RTW rates at 12 and 24 months after BC diagnosis and to identify the factors associated with RTW in this population. Methods In total, 125 employed women from a single institution with newly diagnosed BC were interviewed by telephone at 6, 12, and 24 months after diagnosis. Those who had inoperable or metastatic disease were excluded. Results Overall, RTW rates were 30.3% and 60.4% at 12 and 24 months after BC diagnosis, respectively. Most women reported that they received support from their employer, but only 29.1% reported having been offered work adjustments. In multivariate analysis, the factors associated with positive RTW outcomes included higher household income (odds ratio [OR], 17.76; 95% confidence interval [CI], 3.33-94.75; P = .001), breast-conserving surgery (OR, 9.77; 95% CI, 2.03-47.05; P = .004), and work adjustments (OR, 37.62; 95% CI, 2.03-47.05; P = .004). The factors associated with negative RTW outcomes included adjuvant endocrine therapy (OR, 0.11; 95% CI, 0.02-0.74; P = .023), and depression diagnosed after BC (OR, 0.07; 95% CI, 0.01-0.63; P = .017). Conclusions RTW rates in the current study were lower than those observed in developed countries but similar to the rates among low-income Americans. Workplace adjustments, higher income, breast-conserving surgery, endocrine therapy, and depression after BC played an important role in the RTW decision. Cancer 2018;124:4700-4710. (C) 2018 American Cancer Society.
bookPart Síndrome de compressão medular(2017) FêDE, Angelo Bezerra de Souza; TAKAHASHI, Tiago KenjibookPart Câncer de pulmão(2017) FêDE, Angelo Bezerra de Souza; TAKAHASHI, Tiago Kenji; MAK, Milena Perez; CASTRO JUNIOR, Gilberto deconferenceObject Factors associated with mortality rates of patients with advanced cancer admitted to a specialized intensive care unit(2013) BARIANI, G. M.; CASTRIA, T. B.; ANDRADE, A. M.; FARIA, L. D.; SILVA, D. F.; BRAGHIROLI, M. I.; MIRANDA, V. C.; FEDE, A. B.; HAJJAR, L.; RIECHELMANN, R.bookPart Síndrome de compressão medular(2015) FêDE, Angelo Bezerra de Souza; TAKAHASHI, Tiago KenjiconferenceObject Retrospective analysis of prognostic factors in patients undergoing surgical resection for multiple brain metastases(2014) PETITTO, Carlos; LAGE, Liana Valente; CAIRES, Inacelli Queiroz De Souza; SOUZA, Karla T.; FEDE, Angelo Bezerra de Souza; FEHER, Olavo; HOFF, Paulo M.; CAMARGO, Verldlana; MENCARINI, Ana; MUNHOZ, Rodrigo Ramella; TEIXEIRA, Manoel Jacobsen; LEPSKI, GuilhermebookPart Câncer de pulmão(2015) FêDE, Angelo Bezerra de Souza; TAKAHASHI, Tiago Kenji; MAK, Milena Perez; CASTRO JUNIOR, Gilberto de- Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness(2014) MIRANDA, Vanessa da Costa; FEDE, Angelo Bezerra de Souza; ANJOS, Carlos Henrique dos; SILVA, Juliana Ribeiro da; SANCHEZ, Fernando Barbosa; BESSA, Lyvia Rodrigues da Silva; CARVALHO, Jesus de Paula; ABDO FILHO, Elias; FREITAS, Daniela de; DIZ, Maria del Pilar EstevezObjective. Three cycles of neoadjuvant chemotherapy (NACT) followed by interval debulking (ID) surgery is an alternative for patients with advanced ovarian cancer unresectable disease. This study aimed to determine the efficacy and safety of six cycles of NACT followed by cytoreduction. Methods. Retrospective analysis of all patients with advanced epithelial ovarian cancer, tubal carcinoma, or primary peritoneal carcinoma treated with platinum based NACT between January 2008 and February 2012. Results. Eighty-two patients underwent NACT; 78% and 18.2% had extensive stage IIIC or IV disease at diagnosis, respectively. Their median age was 60 years (41-82). On histology, serous adenocarcinoma was found in 90.2%. Patients did not receive chemotherapy after debulking surgery. 35.4% suffered grade 3/4 toxicity; the most commonly observed toxicities were hematologic and nausea. After NACT, 23.1% experienced clinical complete response, 57.4% partial response, and 12.1% disease progression. Complete resection of all macroscopic and microscopic disease (R0) was performed in 63.7%. Surgical complications were uncommon; however, four (6.2%) patients needed a second procedure due to operative complications and 18 (27.3%) needed blood transfusion after debulking. Over a median follow-up period of 19.2 months, median overall survival and chemotherapy-free interval were 37.5 months (confidence interval not reached) and 16 months, respectively. Conclusion. Six cycles of neoadjuvant carboplatin and paclitaxel was safe and effective and did not increase perioperative or postoperative complications in patients with stage IIIC/IV disease who were unsuitable for optimal PDS. The overall survival of this cohort was higher than that of those treated with ID surgery.
conferenceObject Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features(2013) BARROSO-SOUSA, Romualdo; MUNHOZ, Rodrigo Ramella; FONSECA, Leonardo Gomes; FEDE, Angelo Bezerra de Sousa; LINCK, Rudinei Diogo Marques; MONIZ, Camila Motta Venchiarutti; MAK, Milena Perez; SOUZA, Ciro Eduardo; HOFF, Paulo M.; DZIK, Carlos